Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
KKT-forskningsgruppene i de kliniske avdelingene: Årsrapport 2013 Forskningsgruppeleder: Forskningsgruppe: Kontaktadresse: Forankringsavdeling: Arne Kolstad Immunterapi Avd for Kreftbehandling, OUS Radiumhospitalet Avd for Kreftbehandling For klinikkovergripende forskningsgrupper: Er skriftlig avtale inngått? (kryss av) Ja Nei x Gruppemedlemmer : Legg ved liste hvis det har vært endringer etter okt 2013. Gruppemøter: Hvor mange gruppemøter er avholdt i 2013? (fyll ut) 2 møter Samarbeid: Type forskning i gruppen (kryss av) Avdelinger representert i gruppen (fyll ut) Fagområder representert i gruppen (fyll ut) Profesjoner representert i gruppen (kryss av) Prosjektsamarbeid nasjonalt (oppgi institusjon(er)) Prosjektsamarbeid internasjonalt (oppgi land og institusjon(er)) Basal x Klinisk x Translasjon (kan fylles ut av administrasjonen) x Leger X Helsefag Realister x (Siv.)ing. Annet OUS, Universitetssykehuset Nord-Norge, Bioteknologisenteret UiO Center for Cancer Immunotherapy (CCIT), Herlev University Hospital Netherlands Cancer Institute (NKI), Amsterdam University College London, UCL Cancer Institute Institute of Molecular Immunology, Helmholtz Zentrum München AdaptImmune Ltd, Oxford Stanford University, USA Vanderbilt University, Tennessee, USA Fred Hutchinson Cancer Institute, USA Karolinska Institutet, Sverige Minnesota University USA Mont Sinai School of Medicine, NY, USA Pågående forskningsprosjekter i gruppen (fyll ut eller legg ved liste) Prosjektleder Prosjektnavn Startdato/ måned evt ekstern(e) finansieringskilde(r) Tildelt sum 1 Kalle malmberg 2014 Integrative profiling of human NK cell repertoires / Selective expansion of educated NK cells for cancer therapy NFR, kreftföreningen, HSØ 7000k/år Johanna Olweus Cancer-targeted T cell receptors – the next generation immunotherapeutic drugs CD20-specific T cells in immunotherapy of leukaemia and lymphoma Lymvac-1 cancer vaccine in malignant lymphoma 2010/6 Helse Sør-øst 900.000/år 2009 NFR 1.100k/år 2007/12 2013/9 2012/12 Roche Genterapimidler Nordic Nanovector KKT Lytix BioPharma AS Genterapimidler 1000k Postdoc Fullfinansiering Johanna Olweus Arne Kolstad Arne Kolstad Betalutin anti-CD37 radioimmunotherpy in malignant lymphoma Pål F. Brunsvig LTX-315 clinical trial melanoma DC005 clinical trial in Prostate cancer Ultimovacs clinical trial NSCLC 2009/09 2012/12 Ultimovacs AS Fullfinansiering Targovax clinical trial pancreatic cancer Patient-derived T cell receptors targeting cancer 2012/12 Targovax AS Fullfinansiering 2013/01 Helse Sør Øst Postdoc stipend Phase III trial of DC-based vaccine against brain cancer Identify and characterize therapy-resistant tumour cells in B-cell lymphoma Assessment of aberrant signaling pathways in B-cell lymphoma – prognostic and therapeutic potential New diagnostic markers and targets for therapeutic intervention in B-cell lymphoma 2013/09 Kreftforeningen 2013/01 Kreftforeningen 776k/år 2014 Helse Sør-Øst 900k / år 2014 NFR 2000k / år Svein Dueland Pål F. Brunsvig Svein Dueland Jon Amund Kyte Iver Langmoen Erlend Smeland/ June Myklebust Erlend Smeland/ June Myklebust Erlend Smeland/ June Myklebust Fullfinansiering Fullfinansiering Publikasjoner: legg ved gruppens publikasjonsliste for 2013 se nederst Dr grader avlagt siste år: (fyll ut) 2 Kandidatens navn Olav E. Yri Hovedveileder Harald Holte, Erlend Smeland Dato/måned 4/10-2013 Patentsøknader, Disclosure of invention (DOFI), lisens-/opsjonsavtaler, bedriftsetablering (fyll ut) Avtaleinnehavers navn Johanna Olweus Karl-Johan Malmberg Tiltak og tittel 1.A novel technology platform for epitope discovery 2.Novel peptide targets in lymphoma and leukemia Selective and Controlled Expansion of Educated NK Cells for Cancer Therapy Dato/måned Desember 2012 September 2012 Publikasjoner 2013 Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. Blood. 2014 Jan 7. [Epub ahead of print] PubMed PMID: 24398326. Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation. Eur J Immunol. 2013 Dec 2. doi: 10.1002/eji.201343671. [Epub ahead of print] PubMed PMID: 24293164. Taraldsrud E, Fevang B, Aukrust P, Beiske KH, Fløisand Y, Frøland S, Rollag H, Olweus J. Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to toll-like receptors 7 and 9. Clin Exp Immunol. 2013 Nov 18. doi: 10.1111/cei.12239. [Epub ahead of print] PubMed PMID: 24237110. 3 Kumari S, Wälchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN, Olweus J. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):403-8. doi: 10.1073/pnas.1306549111. Epub 2013 Dec 16. PubMed PMID: 24344295. Behnan J, Isakson P, Joel M, Cilio C, Langmoen IA, Vik-Mo EO, Badn W. Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells. 2013 Dec 3. doi: 10.1002/stem.1614. [Epub ahead of print] PubMed PMID: 24302539. Murrell W, Palmero E, Bianco J, Stangeland B, Joel M, Paulson L, Thiede B, Grieg Z, Ramsnes I, Skjellegrind HK, Nygård S, Brandal P, Sandberg C, Vik-Mo E, Palmero S, Langmoen IA. Expansion of multipotent stem cells from the adult human brain. PLoS One. 2013 Aug 14;8(8):e71334. doi: 10.1371/journal.pone.0071334. eCollection 2013. PubMed PMID: 23967194; PubMed Central PMCID: PMC3743777. Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome. Exp Cell Res. 2013 Aug 15;319(14):2230-43. doi: 10.1016/j.yexcr.2013.06.004. Epub 2013 Jun 18. PubMed PMID: 23791939. Joel M, Sandberg CJ, Boulland JL, Vik-Mo EO, Langmoen IA, Glover JC. Inhibition of tumor formation and redirected differentiation of glioblastoma 4 cells in a xenotypic embryonic environment. Dev Dyn. 2013 Sep;242(9):1078-93. doi: 10.1002/dvdy.24001. Epub 2013 Jul 29. PubMed PMID: 23780720. Berg-Johnsen J, Helseth E, Langmoen IA. Cerebral Revascularization for Skull Base Tumors. World Neurosurg. 2013 Mar 26. pii: S1878-8750(13)00546-9. doi: 10.1016/j.wneu.2013.03.052. [Epub ahead of print] PubMed PMID: 23541748. Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, Brody JD. Signaling pathways in lymphoma: pathogenesis and therapeutic targets. Future Oncol. 2013 Oct;9(10):1549-71. doi: 10.2217/fon.13.113. PubMed PMID: 24106904. Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013 Feb 28;121(9):1604-11. doi: 10.1182/blood-2012-09-457283. Epub 2013 Jan 7. PubMed PMID: 23297126; PubMed Central PMCID: PMC3587323. Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24. PubMed PMID: 23616624; PubMed Central PMCID: PMC3674665. Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, 5 Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevärn B, Olofsson T, Olsson-Strömberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H; Nordic CML Study Group (NCMLSG). Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 2013 Jul;27(7):1520-6. doi: 10.1038/leu.2013.19. Epub 2013 Jan 18. PubMed PMID: 23328954. Os A, Bürgler S, Ribes AP, Funderud A, Wang D, Thompson KM, Tjønnfjord GE, Bogen B, Munthe LA. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep. 2013 Aug 15;4(3):566-77. doi: 10.1016/j.celrep.2013.07.011. Epub 2013 Aug 8. PubMed PMID: 23933259. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer. 2014 Jan 1;134(1):102-13. doi: 10.1002/ijc.28338. Epub 2013 Jul 16. PubMed PMID: 23784959. Bengnér M, Béziat V, Ernerudh J, Nilsson BO, Löfgren S, Wikby A, Malmberg KJ, Strindhall J. Independent skewing of the T cell and NK cell compartments associated with cytomegalovirus infection suggests division of labor between innate and adaptive immunity. Age (Dordr). 2013 Sep 25. [Epub ahead of print] PubMed PMID: 24065293. Béziat V, Traherne JA, Liu LL, Jayaraman J, Enqvist M, Larsson S, Trowsdale J, Malmberg KJ. Influence of KIR gene copy number on natural killer cell education. 6 Blood. 2013 Jun 6;121(23):4703-7. doi: 10.1182/blood-2012-10-461442. Epub 2013 May 1. PubMed PMID: 23637128; PubMed Central PMCID: PMC3674669. Sternberg-Simon M, Brodin P, Pickman Y, Onfelt B, Kärre K, Malmberg KJ, Höglund P, Mehr R. Natural killer cell inhibitory receptor expression in humans and mice: a closer look. Front Immunol. 2013 Mar 26;4:65. doi: 10.3389/fimmu.2013.00065. eCollection 2013. PubMed PMID: 23532016; PubMed Central PMCID: PMC3607804. Béziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Björklund AT, Retière C, Sverremark-Ekström E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale J, Michaëlsson J, Ljunggren HG, Malmberg KJ. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood. 2013 Apr 4;121(14):2678-88. doi: 10.1182/blood-2012-10-459545. Epub 2013 Jan 16. PubMed PMID: 23325834; PubMed Central PMCID: PMC3617633. Vanherberghen B, Olofsson PE, Forslund E, Sternberg-Simon M, Khorshidi MA, Pacouret S, Guldevall K, Enqvist M, Malmberg KJ, Mehr R, Önfelt B. Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood. 2013 Feb 21;121(8):1326-34. doi: 10.1182/blood-2012-06-439851. Epub 2013 Jan 3. PubMed PMID: 23287857. Fløisand Y, Beiske K, Tjønnfjord GE, Heldal D, Bjerkehagen B, Revheim ME, Heim S, Bruland OS, Hall KS, Tierens A, Delabie J. Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin. Case Rep Hematol. 2013;2013:934781. doi: 10.1155/2013/934781. Epub 2013 Dec 17. PubMed PMID: 7 24455338. Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR. The clinical impact of mean vessel size and solidity in breast carcinoma patients. PLoS One. 2013 Oct 11;8(10):e75954. doi: 10.1371/journal.pone.0075954. PubMed PMID: 24146798; PubMed Central PMCID: PMC3795733. Haldorsen K, Bruland O, Appel S, Bolstad AI. Reply to 'comment on no association of primary Sjögren's syndrome with Fcγ receptor gene variants'. Genes Immun. 2013 Dec;14(8):532. doi: 10.1038/gene.2013.51. Epub 2013 Oct 10. PubMed PMID: 24108103. Sapkota D, Costea DE, Ibrahim SO, Johannessen AC, Bruland O. S100A14 interacts with S100A16 and regulates its expression in human cancer cells. PLoS One. 2013 Sep 27;8(9):e76058. doi: 10.1371/journal.pone.0076058. PubMed PMID: 24086685; PubMed Central PMCID: PMC3785438. Rusten E, Rødal J, Bruland Ø, Malinen E. Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapy. Acta Oncol. 2013 Oct;52(7):1378-83. doi: 10.3109/0284186X.2013.813071. Epub 2013 Aug 28. PubMed PMID: 23981046. Houge G, Bruland O, Bjørnevoll I, Hayden MR, Semaka A. De novo Huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype. Neurology. 2013 Sep 17;81(12):1099-100. doi: 10.1212/WNL.0b013e3182a4a4af. Epub 2013 Aug 14. PubMed PMID: 23946314; PubMed Central PMCID: PMC3795589. 8 Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. PubMed PMID: 23863050. Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S, Johannesen TB, Fosså SD. Incidence and mortality of second sarcomas - a population-based study. Eur J Cancer. 2013 Oct;49(15):3292-302. doi: 10.1016/j.ejca.2013.05.017. Epub 2013 Jun 17. PubMed PMID: 23787025. Jebsen NL, Engellau J, Engström K, Bauer HC, Monge OR, Muren LP, Eide GE, Trovik CS, Bruland OS. Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):949-55. doi: 10.1016/j.ijrobp.2013.04.015. Epub 2013 May 29. PubMed PMID: 23725998. Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T. Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Acta Oncol. 2014 Jan;53(1):143-8. doi: 10.3109/0284186X.2013.798428. Epub 2013 May 28. PubMed PMID: 23710697. Berland S, Appelbäck M, Bruland O, Beygo J, Buiting K, Mackay DJ, Karen Temple I, Houge G. Evidence for anticipation in Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2013 Dec;21(12):1344-8. doi: 10.1038/ejhg.2013.71. Epub 2013 Apr 10. 9 PubMed PMID: 23572028; PubMed Central PMCID: PMC3831082. Haldorsen K, Appel S, Le Hellard S, Bruland O, Brun JG, Omdal R, Kristjansdottir G, Theander E, Fernandes CP, Kvarnström M, Eriksson P, Rönnblom L, Herlenius MW, Nordmark G, Jonsson R, Bolstad AI. No association of primary Sjögren's syndrome with Fcγ receptor gene variants. Genes Immun. 2013 Jun;14(4):234-7. doi: 10.1038/gene.2013.12. Epub 2013 Apr 4. PubMed PMID: 23552400. Lagunova Z, Porojnicu AC, Aksnes L, Holick MF, Iani V, Bruland OS, Moan J. Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial. Br J Dermatol. 2013 Aug;169(2):434-40. doi: 10.1111/bjd.12349. PubMed PMID: 23551243. Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland Ø, Dahle J. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. Curr Radiopharm. 2013 Jun 6;6(2):106-16. PubMed PMID: 23551111. Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J. Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts. Curr Radiopharm. 2013 Jun 6;6(2):78-86. PubMed PMID: 23551110. Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol. 2013 May;52(4):776-82. doi: 10.3109/0284186X.2013.770920. Epub 2013 Mar 13. PubMed 10 PMID: 23480638; PubMed Central PMCID: PMC3622233. Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E. Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncol. 2013 Aug;52(6):1160-7. doi: 10.3109/0284186X.2012.728713. Epub 2012 Dec 3. PubMed PMID: 23198721. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland ØS. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013 Mar;11(1):20-6. doi: 10.1016/j.clgc.2012.07.002. Epub 2012 Sep 26. PubMed PMID: 23021204. Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev. 2013 Feb;39(1):18-26. doi: 10.1016/j.ctrv.2012.03.006. Epub 2012 Apr 24. Review. PubMed PMID: 22534284. Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H. High dose chemotherapy with autologous stem cell transplantation for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma. 2014 Jan 16. [Epub ahead of print] PubMed PMID: 24432894. Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE. Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. Epigenetics. 2013 Dec 11 20;9(3). [Epub ahead of print] PubMed PMID: 24362313. Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood. 2013 Dec 19. [Epub ahead of print] PubMed PMID: 24357726. Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE. Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma. PLoS One. 2013 Nov 19;8(11):e79602. doi: 10.1371/journal.pone.0079602. PubMed PMID: 24260260; PubMed Central PMCID: PMC3834187. Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez-Guillermo A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier B. A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. Oncologist. 2013;18(11):1189. doi: 10.1634/theoncologist.2013-0223. Epub 2013 Oct 8. PubMed PMID: 24105750; PubMed Central PMCID: PMC3825302. Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H. Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. Eur J Haematol. 2013 Oct;91(4):332-8. doi: 10.1111/ejh.12171. Epub 2013 Aug 17. PubMed PMID: 23859481. Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg A, 12 Hjalmarsson E, Holte H, Ostenstad B, Brown PD, Smeland EB, Kimby E. Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk Lymphoma. 2013 Jun 14. [Epub ahead of print] PubMed PMID: 23662992. Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol. 2013 Apr 20;31(12):1562-8. doi: 10.1200/JCO.2012.45.3266. Epub 2013 Mar 18. PubMed PMID: 23509321. Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A. Enhancement characteristics of retroperitoneal lymphomatous lymph nodes. Acta Radiol. 2013 Apr 1;54(3):333-9. doi: 10.1258/ar.2012.120679. Epub 2013 Feb 27. PubMed PMID: 23446747. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk Lymphoma. 2013 Oct;54(10):2205-14. doi: 10.3109/10428194.2013.774392. Epub 2013 Apr 2. PubMed PMID: 23391141. Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. 13 Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17. PubMed PMID: 23247661. Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA. Malignant melanoma--diagnosis, treatment and follow-up in Norway. Tidsskr Nor Laegeforen. 2013 Oct 29;133(20):2154-9. doi: 10.4045/tidsskr.12.1416. Review. English, Norwegian. PubMed PMID: 24172628. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013 Sep;62(9):1499-509. doi: 10.1007/s00262-013-1453-3. Epub 2013 Jul 2. PubMed PMID: 23817721; PubMed Central PMCID: PMC3755221. Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun 2. PubMed PMID: 23735514. 14 Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9. doi: 10.1016/j.ejca.2013.01.013. Epub 2013 Feb 21. PubMed PMID: 23433846. Hagness M, Foss A, Egge TS, Dueland S. Patterns of Recurrence After Liver Transplantation for Nonresectable Liver Metastases from Colorectal Cancer. Ann Surg Oncol. 2013 Dec 27. [Epub ahead of print] PubMed PMID: 24370906. Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, Boberg KM, Mathisen O, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013 May;257(5):800-6. doi: 10.1097/SLA.0b013e3182823957. PubMed PMID: 23360920. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11. PubMed PMID: 22967994. Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF. Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta Oncol. 2013 Nov 18. [Epub ahead of print] PubMed PMID: 24237392. 15 Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S. High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment. Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1735-9. doi: 10.4045/tidsskr.13.0319. English, Norwegian. PubMed PMID: 24005713. Laurell A, Kolstad A, Jerkeman M, Räty R, Geisler CH. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial. Leuk Lymphoma. 2013 Aug 28. [Epub ahead of print] PubMed PMID: 23876100. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013 Feb 21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7. PubMed PMID: 23297127; PubMed Central PMCID: PMC3578953. Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95. PubMed PMID: 23267131. 16 17